Gulf South Minority/Underserved Clinical Trials Network (Gulf South M/U CTN)

总体而言，癌症患者患新冠肺炎的风险增加。癌症和新冠肺炎都会不成比例地影响全国的少数民族和服务不足的人群，特别是在路易斯安那州和密西西比州的墨西哥湾南部地区。这些重大的健康差距在生活在农村地区和集中贫困地区(高度贫困)的癌症患者中进一步扩大。因此，迫切需要开发一个新的路易斯安那州癌症-新冠肺炎(LA-癌症-新冠肺炎登记处)登记，以更好地了解当前大流行对南部海湾地区癌症患者的影响。获得的数据将被用来了解新冠肺炎如何影响现有的癌症健康差距，并将为我们迎接新的国家诊断和治疗倡议做好准备。这一补充的父母赠款是海湾南部少数民族/服务不足的临床试验网络(海湾南部CTN)NCORP。墨西哥湾南部CTN是路易斯安那州立大学新奥尔良癌症中心、奥克斯纳临床基金会、玛丽·伯德·珀金斯癌症中心和位于什里夫波特的路易斯安那州立大学费斯特·韦勒癌症中心的合作伙伴关系。他们共同监督着一个由44个临床站点组成的网络，这些网络显著增加了整个地区参加临床试验的癌症患者的人数。大约50%的入选患者是非裔美国人。路易斯安那州肿瘤登记处(LTR)是SEER的登记处，也是南墨西哥湾CTN的合作伙伴。LTR收集该州癌症患者的所有信息，并有法律授权获取他们的所有生物样本和临床信息。就本补编而言，负责监督新冠肺炎应对工作的路易斯安那州卫生研究院和公共卫生办公室已同意建立这一新的登记系统。因此，具体目标是：1)建立路易斯安那州癌症-新冠肺炎登记处，将癌症登记处与路易斯安那州卫生部的新冠肺炎登记处联系起来。2)使用新登记的数据来研究新冠肺炎对路易斯安那州癌症健康差异的影响，以及3)通过路易斯安那州癌症COVID-19登记中心的协调数据收集工作，更有效地参与国家临床和流行病学研究。洛杉矶-癌症-新冠肺炎注册中心将使我们能够识别患有新冠肺炎的癌症患者，识别那些发生感染的高风险患者，并确定冠状病毒“热点”的位置。我们将能够确定新冠肺炎如何影响不同人群以及农村和城市地区癌症健康差异。更重要的是，癌症-COVID19登记中心将通过迅速部署和部署能够部署诊断、治疗或流行病学试验的中心，为我们应对新冠肺炎或其他未来大流行的死灰复燃做好更好的准备。

Cancer patients overall are at increased risk for developing COVID-19. Both cancer and COVID-19 disproportionately affect minority and underserved populations throughout the country and especially in the Gulf South region of Louisiana and Mississippi. These major health disparities are further magnified in cancer patients living in rural areas and regions of concentrated disadvantage (high poverty). Therefore, there is an urgent need to develop a new Louisiana Cancer-COVID-19 (LA-Cancer-COVID-19 Registry) registry to better understand the impact of the current pandemic on cancer patients in the Gulf South Region. The data obtained will be used to understand how COVID-19 has affected existing cancer health disparities and will prepare us for new national diagnostic and treatment initiatives. The parent grant to this supplement is the Gulf South Minority/Underserved Clinical Trials Network (Gulf South CTN) NCORP. The Gulf South CTN is a partnership between LSU Cancer Center – New Orleans, Ochsner Clinic Foundation, Mary Bird Perkins Cancer Center and LSU- Feist Weiller Cancer Center in Shreveport. Together they oversee a network of 44 clinical sites that have significantly increased enrollments of cancer patients into clinical trials throughout the region. Approximately 50% of patients enrolled are African American. The Louisiana Tumor Registry (LTR), a SEER registry, is also a partner in the Gulf South CTN. The LTR collects all information on cancer patients in the state and has legislative mandate to access all their biological samples and clinical information. For the purpose of this Supplement, the LTR and the Office of Public Health at the Louisiana Department of Health, that oversees the response to COVID-19, have agreed to build this new registry. Therefore the Specific Aims are: 1) Develop the Louisiana Cancer – COVID-19 Registry by linking the LTR cancer registry with the Louisiana Department of Health (LDH) COVID-19 registry. 2) Use the data from the new registry to study the effect of COVID-19 on cancer health disparities in Louisiana, and 3) More effectively participate in national clinical and epidemiological studies through the coordinated data collection efforts of the Louisiana CancerCOVID-19 Registry. The LA-Cancer-COVID-19 Registry will allow us to identify cancer patients who have developed COVID-19 and identify those at high risk for developing the infection and to determine the location of coronavirus “hot spots”. We will be able to determine how COVID-19 impacts cancer health disparities in different populations and in rural vs urban locations. More importantly the Cancer-COVID19 Registry will better prepare us for a resurgence of COVID-19 or other future pandemics by rapidly deploy being able to deploy diagnostic, treatment or epidemiological trials.